Amarin Corp. PLC (AMRN) Shares Down 7.8%
Shares of Amarin Corp. PLC (NASDAQ:AMRN) traded down 7.8% during mid-day trading on Thursday . The company traded as low as $2.91 and last traded at $3.06, with a volume of 8,395,848 shares. The stock had previously closed at $3.32.
A number of analysts recently issued reports on the company. Jefferies Group assumed coverage on Amarin Corp. PLC in a report on Thursday, May 12th. They set a “buy” rating and a $3.50 price objective on the stock. Zacks Investment Research lowered Amarin Corp. PLC from a “hold” rating to a “sell” rating in a research note on Tuesday, May 17th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Amarin Corp. PLC in a research note on Monday, May 9th.
The firm has a 50-day moving average price of $2.48 and a 200 day moving average price of $1.87. The firm’s market cap is $566.57 million.
Amarin Corp. PLC (NASDAQ:AMRN) last posted its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The business earned $32.82 million during the quarter, compared to analyst estimates of $29.97 million. During the same quarter last year, the firm earned ($0.15) EPS. The business’s revenue was up 85.4% on a year-over-year basis. Equities research analysts predict that Amarin Corp. PLC will post ($0.53) earnings per share for the current fiscal year.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.